Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852365 · ClinicalTrials.gov registry record · Phase 2
Combined Oral Contraceptive Pill and Resistance Starch
A Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06852365: Recruiting Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by University of Pennsylvania.
NCT06852365 is a Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 100 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06852365, a Phase 2 study of Metabolic Syndrome and Polycystic Ovary Syndrome, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT wheat dextrin
- DRUG Oral Contraceptives, Low-Dose
- DIETARY_SUPPLEMENT Maltodextrin
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What NCT06852365 shows while recruiting
NCT06852365 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which wheat dextrin is the first listed.
NCT06852365 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06852365 about?
NCT06852365 is a clinical study titled "Combined Oral Contraceptive Pill and Resistance Starch". This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.
What is the current status of trial NCT06852365?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-10. Estimated completion is 2028-04.
What conditions does trial NCT06852365 study?
This clinical trial studies the following conditions: Metabolic Syndrome, Polycystic Ovary Syndrome.
What interventions are being tested in trial NCT06852365?
The interventions under investigation include: wheat dextrin (DIETARY_SUPPLEMENT), Oral Contraceptives, Low-Dose (DRUG), Maltodextrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06852365?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852365 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06852365's enrollment target sits among peer trials
100 32nd of 102 higher than 70 of 102 other Metabolic Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolic Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health
RECRUITING · Phase 2
-
Causal Mechanisms in Adolescent Arterial Stiffness
ACTIVE NOT RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome
COMPLETED · Phase 2
-
Effects of Human Leptin Replacement
COMPLETED · Phase 2
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI